Vaccine for Rabies After Bite

AIM Honor is a supplier of Vaccine for Rabies After Bite from China. This product comes in two types: conventional Vero cell rabies vaccine and the next-generation serum-free Vero cell rabies vaccine. The former uses mature technology and has a stable supply, while the latter avoids risks associated with bovine serum through a completely serum-free culture process.

Both products achieve a 100% antibody seroconversion rate within 14 days and are administered via intramuscular injection, suitable for emergency prevention and control needs in various dog bite exposure scenarios. It is a core solution for post-exposure rabies prevention!

What is the Vaccine for Rabies After Bite?

This vaccine is a specialized preparation for emergency prevention after exposure to dog bites. The standard version has the national drug approval number S20073014 and has been supplied to over 2,000 disease control institutions in China for a long time. The serum-free version is an innovative upgraded product, which has completed Phase III clinical trials and its marketing application has been accepted by the CDE (China Center for Drug Evaluation). Its core advantage lies in its completely serum-free culture process – from Vero cell resuscitation and expansion to virus culture, no bovine serum is added throughout the entire process, completely eliminating the risks of batch-to-batch quality fluctuations, viral contamination, and allergic reactions caused by bovine serum. This process complies with WHO guidelines on avoiding the use of bovine-derived raw materials in biological products.

For graded prevention and control needs after dog bite exposure, Class II exposure (non-bleeding bites/scratches) can be vaccinated directly according to a 5-dose schedule on days 0, 3, 7, 14, and 28; Class III exposure (bleeding bites, mucous membrane contact) requires combined use with rabies immunoglobulin (20 IU/kg).

100% seroconversion is achieved 14 days after vaccination, and the neutralizing antibody GMC value far exceeds the WHO protection threshold of 0.5 IU/ml, with immunity lasting for more than 3 months, building a strong immune barrier for people exposed to dog bites.

Product Specification

Core Advantages

The conventional version has high cost-effectiveness and large supply, meeting the mass emergency vaccination needs of primary medical institutions; the serum-free version has advanced technology, adapting to high-end scenarios such as top three hospitals and foreign-related medical institutions, as well as allergic populations, filling the gap in the domestic serum-free rabies vaccine market.

Both products can achieve 100% antibody seroconversion within 14 days; the serum-free version also supports the WHO simplified 4-dose schedule, reducing the number of vaccinations while ensuring immune effect and improving the vaccination compliance of exposed populations.

The conventional version complies with the 2020 edition of the Pharmacopoeia of the People's Republic of China Volume III, with a 100% batch release qualification rate for 17 years; the clinical data of the serum-free version has been accepted by CDE, and the process complies with international biopharmaceutical raw material usage standards.

Application Scenarios

Emergency medical scenarios: Used for emergency vaccination within 24 hours after dog bites in emergency centers and trauma hospitals to quickly initiate immune protection.

Primary prevention and control network: Community health service centers and township health centers provide regular vaccination services for dog bite populations in rural and suburban areas.

Special population vaccination: The serum-free version can be used for children, the elderly and allergic dog bite populations to reduce vaccination risks.